Halozyme Therapeutics Q3 EPS $(0.17) Misses $(0.12) Estimate, Sales $46.23M Miss $54.81M Estimate

Halozyme Therapeutics (NASDAQ:HALO) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.12) by 41.67 percent. This is a 10.53 percent increase over losses of $(0.19) per

Benzinga · 11/12/2019 21:46

Halozyme Therapeutics (NASDAQ:HALO) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.12) by 41.67 percent. This is a 10.53 percent increase over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $46.23 million which missed the analyst consensus estimate of $54.81 million by 15.65 percent. This is a 80.90 percent increase over sales of $25.556 million the same period last year.